Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 184,844 | 166,444 | 137,308 | 113,374 | 51,870 |
| Receivables | 47,031 | 66,223 | 72,809 | 61,538 | 34,368 |
| Inventories | 15,610 | 18,643 | 16,708 | 19,732 | 16,243 |
| TOTAL | $252,955 | $258,336 | $234,657 | $203,782 | $113,831 |
| Non-Current Assets | |||||
| PPE Net | 1,222 | 1,473 | 1,714 | 1,904 | 2,200 |
| Intangibles | 59,044 | 59,044 | 59,044 | 59,044 | 59,044 |
| Other Non-Current Assets | 63,344 | 45,299 | 50,180 | 45,455 | 45,595 |
| TOTAL | $123,610 | $105,816 | $110,938 | $106,403 | $106,839 |
| Total Assets | $376,565 | $364,152 | $345,595 | $310,185 | $220,670 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 21,185 | 10,087 | 11,554 | 12,658 | 15,180 |
| Accrued Expenses | 121,716 | 106,420 | 91,615 | 71,337 | 63,460 |
| Other current liabilities | 17,356 | 12,991 | 10,016 | 5,991 | 2,274 |
| TOTAL | $162,938 | $133,379 | $118,717 | $91,227 | $80,914 |
| Non-Current Liabilities | |||||
| Long Term Debt | 48,250 | 47,641 | 47,062 | 46,511 | 38,693 |
| Deferred Revenues | 2,681 | 3,881 | 5,532 | 1,241 | N/A |
| Other Non-Current Liabilities | 132,767 | 141,540 | 150,592 | 147,866 | 150,248 |
| TOTAL | $181,017 | $189,181 | $197,654 | $194,377 | $188,941 |
| Total Liabilities | $343,955 | $322,560 | $316,371 | $285,604 | $269,855 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 267,879 | 265,366 | 265,145 | 262,636 | 236,231 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,683,705 | -1,671,461 | -1,672,001 | -1,672,248 | -1,678,360 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $32,610 | $41,592 | $29,224 | $24,581 | $-49,185 |
| Total Liabilities And Equity | $376,565 | $364,152 | $345,595 | $310,185 | $220,670 |